Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV

PHASE3TerminatedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

December 31, 2004

Conditions
Hepatitis B
Interventions
DRUG

Clevudine

Trial Locations (30)

Unknown

St. Mercy's Hospital, Bupyoung-dong

Pusan Paik Hospital, Gaegeum-dong

Kangbuk Samsung Hospital, Pyoung-dong

Keimyumg University Dongsan Medical Center, Jung-gu

Chonnam National University Hospital, Hak-1-dong

Korea University Guro Hospital, Seoul

Wonkwang University Hospital, Iksan

Chonbuk National University Hospital, Jeonju

Seoul National University Hospital, Seoul

Inha University Hospital, Sinhŭng-dong

Seoul Asan Medical Center, Pungnap-dong

Yongdong Severance Hospital, Togok-tong

St. Holly Family Mary's Hospital, Bucheonae

National Cancer Center, Ilsan-gu

Pochon CHA University Hospital, Seongnam-gu

Yeungnam University Medical Center, Dae Myoung-dong

Gil Medical Center, Incheon

Nowon Eulji Hospital, Hagyeil-tong

St. Vincent's Hospital, Chi-dong

Pusan National University Hospital, Ami-dong

Kosin Medical Center, Amnam-dong

KangNam St. Mary's Hospital, Banpo-dong

Severance Hospital, Shinchon- Dong

Seoul Paik Hospital, Jeo-dong

Samsung Medical Center, Ilwon-dong

Korea University Anam Hospital, Anam-dong

Ehwa Womans University Mokdong Hospital, Mokdong

Kangnam Sacred Heart Hospital, Daelim-dong

Soon Chun Hyang University Hospital, Hannam-dong

St. Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Bukwang Pharmaceutical

INDUSTRY

NCT00313274 - Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV | Biotech Hunter | Biotech Hunter